8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

424B5 - PMGC Holdings Inc. (0001840563) (Filer)

SCHEDULE 13G/A - PMGC Holdings Inc. (0001840563) (Subject)

EFFECT - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

S-1/A - PMGC Holdings Inc. (0001840563) (Filer)

10-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

3/A - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

3/A - Elevai Labs Inc. (0001840563) (Issuer)

3/A - Elevai Labs Inc. (0001840563) (Issuer)

NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13D - Elevai Labs Inc. (0001840563) (Subject)

Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive's nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. NEWPORT BEACH, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Ho

NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, cash-flow positive information technology ("IT") custom packaging company. About the Target Company Founded in 2011 and headquartered in Southern California, the Target is a well-established provider of custom packaging solutions for IT products, serving over 300 commercial clients—including data centers, technology manufacturers, and IT service providers. With close to 15 years of uninterrupted operations, the compan

Northstrive Biosciences and Yuva Biosciences' collaboration will leverage MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level. NEWPORT BEACH, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive" or "Northstrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," "we," or "our"), announced today th

NEWPORT BEACH, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our") today announced that it has filed its Annual Report on Form 10-K ("Annual Report") for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission ("SEC"). The Annual Report is available on the SEC's website at www.sec.gov under the company's filings, as well as on the Company's investor relations website. PMGC remains dedicated to innovative solutions and delivering long-term value for its shareholders. As part of its strategic growth initiatives, the Company has engaged in an active search for acquisition opportunities invo

The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increasing meat or milk consumption rates, coupled with rising concerns about food-borne diseases.(1)Northstrive Biosciences Inc.'s amendment to its existing licensing agreement allows the company to develop and commercialize a comprehensive range of animal health products, including pharmaceuticals and feed additives. The company believe

New York, New York, March 24, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") for its client PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company"), a diversified holding company. Under the terms of the securities purchase agreement, the Company has agreed to sell to several investors for the purchase and sale of an aggregate of 294,450 of the Company's common stock, par value $0.0001 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a

NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company's common stock, par value $0.0001 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market under Nasdaq. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.001 per share. Following the offering the Company will have appr

NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our") today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company's Form 8-K filings on www.sec.gov. The Company will consider repurchasing additional shares from other investors who wish to sell, subject to market conditions and other considerations. Shareholders interested in discussing potential repurchases are encouraged to contact the Company directly in writing and mail request the company's headquarters in Newport Beach, California.

Northstrive Biosciences Inc. has scheduled a pre-IND meeting with the U.S. Food and Drug Administration for April 23, 2025.EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. NEWPORT BEACH, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), announced that it has scheduled a pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") for Wednesday, April 23, 2025. Northstrive will have a Type

NEWPORT BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-7 reverse stock split (the "Split") of its issued and outstanding common stock, par value $0.0001 per share ("Common Stock"), effective at midnight, Eastern time, on March 10, 2025. Key Details of the Reverse Stock Split: Conversion Ratio: Every 7 shares of issued and outstanding Common Stock will be automatically consolidated into one share, with no further action required from shareholders.Fractional Shares: Shareholders entitled to fractional shares will receive one full share for each fractional portion.Updated Stock Identifi